Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s ALIMTA® (pemetrexed for injection) and Merck’s KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
Source: - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Related Links:

Publication date: Available online 17 July 2018Source: The Annals of Thoracic SurgeryAuthor(s): Ju-Dong Li, Zi-Long Xiao, Xiao-Xiang Hou
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Source: Journal of Biopharmaceutical Statistics - Category: Statistics Authors: Source Type: research
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his view of PDL-1 expression and patient selection Author: obr Added: 07/17/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Condition:   Quality of Life Interventions:   Combination Product: concurrent chemoradiotherapy (CCRT);   Drug: Endostar for one cycle;   Drug: Endostar for two cycles Sponsors:   Affiliated Hospital of North Sichuan Medical College;   Jiangsu Simcere Pharmaceutical Co., Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
The Society for Immunotherapy of Cancer (SITC) published the first clinical immunotherapy treatment guidelines for non-small cell lung cancer today, providing oncologists and other advance practice...(PRWeb July 17, 2018)Read the full story at
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
This study aims to identify different expression patterns of fifteen ...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
To investigate the incidence of radiation esophagitis (RE) and tumor local control using esophagus sparing technique in locally advanced non-small cell lung cancer (LANSCLC) treated by simultaneous integrated ...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
What is the key question?
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractLung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment a pproach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for u...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Immunotherapy,Volume 10, Issue 9, Page 797-805, July 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Pharmaceuticals | Study